I'm with you on looking forward to the NIH topline data.
It's unfortunate that this wait has been so costly and unnecessary. We know that our work on using CRP as a biomarker has been accepted for publication. I personally think that peer review is just as important to us as TLD. But I'll damn sure take the release of both.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.